TriSalus Life Sciences (TLSIW) Cash from Operations (2021 - 2026)

TriSalus Life Sciences has reported Cash from Operations for 6 years, with the latest figure at 6480000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 44.03% year-over-year to 6480000.0; the trailing twelve-month figure through Mar 2026 stood at 19993000.0 (up 42.01% YoY), and the FY2025 full-year result was 18012000.0, up 55.9% from the prior year.
• Cash from Operations for Q1 2026 stood at 6480000.0, down from 2484000.0 in the prior quarter.
• The five-year high for Cash from Operations was 425954.0 in Q1 2022, with the low at 22880298.0 in Q3 2022.
• Historically, Cash from Operations has averaged 8719176.47 across 5 years, with a median of 8310000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Operations plunged 6166.19% — and 2025, when it surged 65.81%.
• TriSalus Life Sciences' Cash from Operations stood at 8310000.0 in 2022, then retreated by 10.43% to 9177000.0 in 2023, then jumped by 37.81% to 5707000.0 in 2024, then jumped by 56.47% to 2484000.0 in 2025, then slumped by 160.87% to 6480000.0 in 2026.
• The last three Cash from Operations figures came in at 6480000.0 (Q1 2026), 2484000.0 (Q4 2025), and 3709000.0 (Q3 2025), per Business Quant data.